Business / Finance

RSS

OMICS Group acquires International Journal of Emergency Health

OMICS Group proudly announces the acquisition of International Journal of Emergency Health, a mental health emergency or mental health crisis research based journal. IJEMH, OMICS Group's latest acquisition, is a MEDLINE indexed journal which was initiated in 1999.

7 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation.

7 Jan 2014

Bunker Vein and Imaging Center starts second location in Round Rock

Bunker Vein and Imaging Center is proud to announce its second location, which opened this month in Round Rock, Texas. Dr. Stephen Bunker and his medical team have been treating patients with varicose veins, spider veins and venous disease for over five years in the Central Austin area.

7 Jan 2014

JLR Medical Group becomes founding partner in U.S. Anesthesia Partners

JLR Medical Group, one of Florida's largest anesthesia practices, today announced it will become a founding partner in U.S. Anesthesia Partners ("USAP"), an anesthesia-focused physician services organization.

7 Jan 2014

Pinnacle Anesthesia to become founding partner in U.S. Anesthesia Partners

Pinnacle Anesthesia today announced it will become a founding partner in U.S. Anesthesia Partners, an anesthesia-focused physician services organization.

7 Jan 2014

Ossianix forms strategic research partnership with Lundbeck

Ossianix, Inc. today announced a strategic research collaboration with Lundbeck A/S. This collaboration follows a previous investment in 2012. The collaboration uses Ossianix's innovative single domain antibody platform based on the shark VNAR structure and will focus on two projects.

6 Jan 2014

Portage acquires approximately 54% equity in Biohaven

Portage Biotech Inc., is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited, a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months.

6 Jan 2014

Johns Hopkins Kimmel Cancer Center scientists to receive $90M in new funding for cancer research

cientists at the Johns Hopkins Kimmel Cancer Center will receive $90 million in new funding as part of a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, to six U.S. institutions. The new award is among the largest for a single private gift to cancer research.

6 Jan 2014

Acadia Healthcare expands geographic presence in the US

Acadia Healthcare Company, Inc. today announced the acquisition of inpatient psychiatric facilities in Seattle, Washington, and Riverside, California, expanding the Company's geographic presence to two new states. Effective, December 1, 2013, the Company completed the purchase of an acute inpatient psychiatric facility from Highline Medical Center, a nonprofit healthcare system headquartered in Seattle.

6 Jan 2014

Thermo Fisher Scientific agrees to sell three businesses to GE Healthcare for $1.06 billion

Thermo Fisher Scientific, the world leader in serving science, today announced that it has signed an agreement to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare, a unit of General Electric Company, for approximately $1.06 billion. The businesses will become part of GE Healthcare's Life Sciences division.

6 Jan 2014

Cord Blood America achieves AABB accreditation for cell therapy activity

Cord Blood America, Inc. today announced it has achieved AABB accreditation for cell therapy activity associated with cord blood processing, storage and distribution.

6 Jan 2014

BioLife Solutions announces preliminary revenue of $9 million for 2013

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013.

6 Jan 2014

Aratana Therapeutics announces acquisition of Okapi Sciences NV

Aratana Therapeutics, Inc., a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.

6 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

Henry Schein signs agreement to acquire five companies from Arseus

Henry Schein, Inc., the world's largest provider of healthcare products and services to office-based dental, animal health and medical practitioners, today announced the signing of an agreement that will further strengthen its European dental and technology businesses.

6 Jan 2014

Metabolon raises $15 million in Series E financing

Metabolon, Inc., a world leader in metabolomics-based diagnostic tests and research services, announced today that it has raised $15 million in a Series E financing through the issuance of preferred stock.

3 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

Lhasa purchases Granary Wharf House for new international Headquarters

Lhasa Limited, a leading global supplier of knowledge-based software and associated databases for use in toxicity, metabolism and the related sciences, today announces the purchase of Granary Wharf House, Leeds, as its new international Headquarters.

3 Jan 2014